Danaher Takes Interest in Life Sciences Firm Catalent
(Bloomberg) -- Life sciences company Danaher Corp. has expressed takeover interest in contract manufacturer Catalent Inc., according to people familiar with the matter.
Most Read from Bloomberg
Commodity Trader Trafigura Faces $577 Million Loss After Uncovering Nickel Fraud
Russia Blames US for Nord Stream Blasts, Threatens Consequences
China’s Balloon Was Capable of Spying on Communications, US Says
Chinese Balloon Was Part of Years-Long Spying Program, US Says
Meta Asks Many Managers to Get Back to Making Things or Leave
Catalent’s shares rose almost 20% to $67 in New York trading Monday for their biggest-ever one-day jump, pushing up the company’s market value to $12 billion.
The overtures by Danaher in recent months valued Catalent at a significant premium, the people said, asking not to be identified because the matter is private. It’s unclear how Catalent will proceed or whether it’s receptive to a takeover offer, the people said. A deal isn’t imminent, they added.
“As a matter of company policy, Catalent does not comment on market rumors or speculation,” a representative said in an emailed statement. A representative for Danaher didn’t respond to a request for comment.
Catalent, based in Somerset, New Jersey provides delivery technologies and development solutions for drugs, biologics and consumer health products. The manufacturer has gained prominence during the coronavirus pandemic, helping to produce more than a billion Covid-19 vaccines and treatments in partnership with companies including Moderna Inc., Johnson & Johnson and AstraZeneca Plc.
The company’s shares more than tripled in the first year of the pandemic but before Monday had fallen about 60% since their peak in September 2021.
Danaher has become a life sciences focused company since spinning out its industrial business arm Fortive Corp. in 2016. Shares in the Washington-based company fell 2.3% to $263.75 Monday, giving it a market value of more than $192 billion.
While Danaher is known in the industry as a serial acquirer, it hasn’t announced any major deals since 2021, when it bought Aldevron, a maker of proteins used in vaccines and research, for $9.6 billion.
A deal uniting Danaher and Catalent would be one of the largest transactions this year, in what’s been a sleepy market for dealmaking, with volumes down two-thirds globally. That said, US mining powerhouse Newmont Corp. overnight offered to buy Australia’s Newcrest Mining Ltd. in a $17 billion deal, which would be the largest deal this year if completed.
--With assistance from Riley Griffin.
(Updates with closing share price in second paragraph.)
Most Read from Bloomberg Businessweek
Brazil’s Richest Man Loses Billions as His M&A Machine Breaks Down
©2023 Bloomberg L.P.